EC
PALI icon

EntryPoint Capital’s Palisade Bio PALI Stock Holding History

EntryPoint Capital’s Portfolio PALI Stock Details PALI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$139K Buy
+79,495
New +$145K 0.04% 682

Other funds holding PALI

Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
BGI
B Group Inc Dallas, Texas $135M AUM 80% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

EntryPoint Capital's PALI Position: Q1 2026 in Review

EntryPoint Capital opened a new position in Palisade Bio (PALI) in Q1 2026: 79,495 shares worth $139K. The stake represents 0.04% of the portfolio and ranks #682 among its holdings.

96 funds tracked by Wall St. Rank hold PALI as of Q1 2026.

  • EntryPoint Capital held 79,495 shares of Palisade Bio worth $139K as of Q1 2026.
  • Palisade Bio was a new EntryPoint Capital position in Q1 2026.
  • Palisade Bio made up 0.04% of EntryPoint Capital's portfolio in Q1 2026, its #682 holding.
  • 96 funds tracked by Wall St. Rank held Palisade Bio as of Q1 2026.

Based on EntryPoint Capital's 13F filing for Q1 2026, filed 14 May 2026.